The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,346 GBX | +1.28% | +0.41% | +16.47% |
06-03 | Global markets live: GSK, Walt Disney, Blackstone, Boeing, Microsoft... | |
06-03 | ASTRAZENECA : JP Morgan remains its Buy rating | ZD |
(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.
The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)
1st Jan change | Capi. | |
---|---|---|
+16.47% | 240B | |
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.37% | 285B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B | |
+1.81% | 162B |